Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the drug, baricitinib, is safe and effective in
reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with
APOL1- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated
chronic kidney disease due to hypertension (HTN-CKD).
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborators:
Eli Lilly and Company National Institute on Minority Health and Health Disparities (NIMHD)